| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5524 | 2010 |
| A framework for advancing our understanding of cancer-associated fibroblasts E Sahai, I Astsaturov, E Cukierman, DG DeNardo, M Egeblad, RM Evans, ... Nature Reviews Cancer 20 (3), 174-186, 2020 | 2996 | 2020 |
| Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial RP DeMatteo, KV Ballman, CR Antonescu, RG Maki, PWT Pisters, ... The lancet 373 (9669), 1097-1104, 2009 | 1748 | 2009 |
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised … GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ... The Lancet 381 (9863), 295-302, 2013 | 1570 | 2013 |
| Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the … CD Blanke, C Rankin, GD Demetri, CW Ryan, M Von Mehren, ... Journal of clinical oncology 26 (4), 626-632, 2008 | 1380 | 2008 |
| NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors GD Demetri, M Von Mehren, CR Antonescu, RP DeMatteo, KN Ganjoo, ... Journal of the National Comprehensive Cancer Network 8 (Suppl_2), S-1-S-41, 2010 | 1339 | 2010 |
| Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ... The Lancet Oncology 18 (11), 1493-1501, 2017 | 1277 | 2017 |
| Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011 | 1154 | 2011 |
| NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines GD Demetri, RS Benjamin, CD Blanke, JY Blay, P Casali, H Choi, ... Journal of the National Comprehensive Cancer Network 5 (S2), S-1-S-29, 2007 | 1136 | 2007 |
| Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation CR Antonescu, P Besmer, T Guo, K Arkun, G Hom, B Koryotowski, ... Clinical cancer research 11 (11), 4182-4190, 2005 | 1002 | 2005 |
| Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor MC Heinrich, RG Maki, CL Corless, CR Antonescu, A Harlow, D Griffith, ... Journal of clinical oncology 26 (33), 5352-5359, 2008 | 995 | 2008 |
| Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses S Gnjatic, D Atanackovic, E Jäger, M Matsuo, A Selvakumar, NK Altorki, ... Proceedings of the National Academy of Sciences 100 (15), 8862-8867, 2003 | 994 | 2003 |
| Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ... New England Journal of Medicine 363 (18), 1727-1733, 2010 | 980 | 2010 |
| Comprehensive and integrated genomic characterization of adult soft tissue sarcomas AJ Lazar, MD McLellan, MH Bailey, CA Miller, EL Appelbaum, MG Cordes, ... Cell 171 (4), 950-965, 2017 | 919 | 2017 |
| Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized … GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ... Journal of Clinical Oncology 34 (8), 786-793, 2016 | 884 | 2016 |
| Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for … RG Maki, JK Wathen, SR Patel, DA Priebat, SH Okuno, B Samuels, ... Journal of Clinical Oncology 25 (19), 2755-2763, 2007 | 883 | 2007 |
| Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ... Journal of Clinical Oncology 20 (12), 2824-2831, 2002 | 834 | 2002 |
| Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial P Schöffski, S Chawla, RG Maki, A Italiano, H Gelderblom, E Choy, ... The Lancet 387 (10028), 1629-1637, 2016 | 830 | 2016 |
| Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy J Barretina, BS Taylor, S Banerji, AH Ramos, M Lagos-Quintana, ... Nature genetics 42 (8), 715-721, 2010 | 819 | 2010 |
| Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) RP DeMatteo, JS Gold, L Saran, M Gönen, KH Liau, RG Maki, S Singer, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 686 | 2008 |
Jean-yves BlayProfesseur de Cancérologie Centre Leon Berard & University Claude Bernard Lyon IVerified email at lyon.unicancer.fr
